The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats

The selective serotonin (5-HT) reuptake inhibitor, citalopram, is a racemic mixture of an S(+)- and R(-)-enantiomer, escitalopram and R-citalopram, respectively. The present study compares the effects of escitalopram, R-citalopram and citalopram on extracellular levels of 5-HT in the frontal cortex of freely moving rats. In addition, co-injection of escitalopram and R-citalopram (ratios 1:2 and 1:4) were assessed. In some experiments escitalopram and R-citalopram were infused into the frontal cortex by reverse microdialysis. Finally, the extracellular level of escitalopram in the frontal cortex was studied after administration of escitalopram alone or in combination with R-citalopram. Escitalopram (1.0-3.9 mg/kg, s.c.) produced a greater maximal increase in extracellular 5-HT than citalopram (2.0-8.0 mg/kg, s.c.). R-citalopram (15.6 mg/kg s.c.) did not affect the 5-HT levels. When co-injected, R-citalopram counteracted the escitalopram-induced increase in extracellular 5-HT levels. Local infusion of the two enantiomers into the frontal cortex produced a similar inhibitory response. R-citalopram did not influence the extracellular levels of escitalopram and therefore does not exert its effect via a pharmacokinetic interaction with escitalopram. In conclusion, the 5-HT-reuptake inhibitory activity of citalopram resides in escitalopram, and the R-enantiomer counteracts this effect. This observation would predict an improved clinical profile of escitalopram compared to citalopram.

[1]  Yves Chaput,et al.  Effects of a selective 5-HT reuptake blocker, citalopram, on the sensitivity of 5-HT autoreceptors: Electrophysiological studies in the rat brain , 1986, Naunyn-Schmiedeberg's Archives of Pharmacology.

[2]  C. Montigny,et al.  Presynaptic and postsynaptic modifications of the serotonin system by long-term administration of antidepressant treatments. An in vivo electrophysiologic study in the rat. , 1991, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[3]  Trevor Sharp,et al.  Inhibition of median and dorsal raphe neurones following administration of the selective serotonin reuptake inhibitor paroxetine , 1995, Naunyn-Schmiedeberg's Archives of Pharmacology.

[4]  R. Samanin,et al.  Chronic treatment with citalopram facilitates the effect of a challenge dose on cortical serotonin output: role of presynaptic 5-HT1A receptors. , 1994, European journal of pharmacology.

[5]  Jack M Gorman,et al.  Efficacy Comparison of Escitalopram and Citalopram in the Treatment of Major Depressive Disorder: Pooled Analysis of Placebo-Controlled Trials , 2002, CNS Spectrums.

[6]  P. Blier,et al.  Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. , 1995, Journal of clinical psychopharmacology.

[7]  O. Olesen,et al.  Studies on the Stereoselective Metabolism of Citalopram by Human Liver Microsomes and cDNA-Expressed Cytochrome P450 Enzymes , 1999, Pharmacology.

[8]  C. de Montigny,et al.  Effect of Pindolol on the Function of Pre- and Postsynaptic 5-HT1A Receptors: In Vivo Microdialysis and Electrophysiological Studies in the Rat Brain , 1996, Neuropsychopharmacology.

[9]  C. Montigny,et al.  Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists , 1996, Trends in Neurosciences.

[10]  W. Burke,et al.  Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. , 2002, The Journal of clinical psychiatry.

[11]  G. Grollier,et al.  Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans. , 1997, Chirality.

[12]  B. Pollock,et al.  Plasma levels of citalopram enantiomers and metabolites in elderly patients. , 1997, Psychopharmacology bulletin.

[13]  P. Plenge,et al.  Affinity modulation of [3H]imipramine, [3H]paroxetine and [3H]citalopram binding to the 5-HT transporter from brain and platelets. , 1991, European journal of pharmacology.

[14]  D. Bakish,et al.  Fast onset: an open study of the treatment of major depressive disorder with nefazodone and pindolol combination therapy , 1997 .

[15]  C. Sánchez,et al.  Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities , 2003, Psychopharmacology.

[16]  John J. B. Allen,et al.  Tryptophan depletion and depressive vulnerability , 1999, Biological Psychiatry.

[17]  U. Lepola,et al.  Escitalopram is efficacious and well tolerated in the treatment of depression in primary care , 2002, European Neuropsychopharmacology.

[18]  C. Naranjo,et al.  Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram , 2001, European Neuropsychopharmacology.

[19]  G. Paxinos,et al.  The Rat Brain in Stereotaxic Coordinates , 1983 .

[20]  Connie Sanchez,et al.  Escitalopram (S-enantiomer of citalopram): clinical efficacy and onset of action predicted from a rat model. , 2001 .

[21]  U. Lepola,et al.  Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. , 2003 .

[22]  P. Grillner,et al.  5-HT1A receptor antagonists increase the activity of serotonergic cells in the dorsal raphe nucleus in rats treated acutely or chronically with citalopram , 1995, Naunyn-Schmiedeberg's Archives of Pharmacology.

[23]  K. Audus,et al.  Transport mechanisms for the antidepressant citalopram in brain microvessel endothelium , 1999, Brain Research.

[24]  P. Plenge,et al.  Antidepressive drugs can change the affinity of [3H]imipramine and [3H]paroxetine binding to platelet and neuronal membranes. , 1985, European journal of pharmacology.

[25]  KA Smith,et al.  Relapse of depression after rapid depletion of tryptophan , 1997, The Lancet.

[26]  H. Miller,et al.  The use of tryptophan depletion to evaluate central serotonin function in depression and other neuropsychiatric disorders , 1993, International clinical psychopharmacology.

[27]  C. Sánchez,et al.  Escitalopram: A comparative in vitro study of 5-HT uptake inhibition and binding in a COS-1 cell line expressing the human 5-HT transporter , 2002, European Neuropsychopharmacology.

[28]  K. Bogeso,et al.  The pharmacological effect of citalopram resides in the (S)-(+)-enantiomer , 2005, Journal of Neural Transmission / General Section JNT.

[29]  G. Martin,et al.  5-HT Receptor Classification and Nomenclature: Towards a Harmonization with the Human Genome , 1997, Neuropharmacology.

[30]  U. Klotz,et al.  Stereoselective HPLC-assay for citalopram and its metabolites. , 2000, Therapeutic drug monitoring.

[31]  C. Nemeroff,et al.  Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine , 2001, Biological Psychiatry.

[32]  M. Tome,et al.  Paroxetine and pindolol: a randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency , 1997, International clinical psychopharmacology.

[33]  C. Montigny,et al.  Modification of serotonergic neuron properties by long-term treatment with serotonin reuptake blockers. , 1990, The Journal of clinical psychiatry.